• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Miromatrix Medical Inc.

    12/13/23 9:12:50 AM ET
    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MIRO alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-40518
    Issuer: Miromatrix Medical Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 10399 West 70th Street
    Eden Prairie MINNESOTA 55344
    Telephone number: (952) 942-6000
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-12-13 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MIRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MIRO

    DatePrice TargetRatingAnalyst
    7/19/2021$22.00Buy
    Craig Hallum
    More analyst ratings

    $MIRO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Miromatrix Medical Inc.

      15-12G - Miromatrix Medical Inc. (0001527096) (Filer)

      12/26/23 6:02:20 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Miromatrix Medical Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update

      8-K - Miromatrix Medical Inc. (0001527096) (Filer)

      12/18/23 4:30:50 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Miromatrix Medical Inc.

      EFFECT - Miromatrix Medical Inc. (0001527096) (Filer)

      12/18/23 12:15:26 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Leadership Updates

    Live Leadership Updates

    See more
    • ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

      DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i

      1/9/23 6:00:00 AM ET
      $AXGN
      $MIRO
      $VRAY
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Miromatrix Appoints Jack Lake, M.D., as Medical Director

      EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today that it has appointed Jack Lake, M.D. as the Company's new Medical Director. Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center. Dr. Lake will serve as Miromatrix's Medical Director while remaining in his current roles at the Universit

      8/10/22 7:00:00 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Miromatrix Names Jim Douglas as New Chief Financial Officer

      EDEN PRAIRIE, Minn., March 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced the appointment of Jim Douglas as the Company's new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance. "On behalf of everyone at Miromatrix and our Board of Directors, I want to thank Brian for his many contributions duri

      3/1/22 5:15:00 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Miromatrix Medical Inc. (Amendment)

      SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)

      2/14/24 5:00:01 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Miromatrix Medical Inc. (Amendment)

      SC 13G/A - Miromatrix Medical Inc. (0001527096) (Subject)

      2/14/24 1:59:27 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Miromatrix Medical Inc.

      SC 13D - Miromatrix Medical Inc. (0001527096) (Subject)

      12/22/23 9:51:15 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

      United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on Decem

      12/13/23 9:15:00 AM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

      United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. ("Merger Sub"), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on December 11, 2023. Contine

      12/12/23 6:00:00 AM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Miromatrix Reports Third Quarter 2023 Results

      EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

      11/14/23 4:05:00 PM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MIRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MIRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • New insider United Therapeutics Corp claimed ownership of 27,419,228 shares (SEC Form 3)

      3 - Miromatrix Medical Inc. (0001527096) (Issuer)

      12/14/23 2:06:09 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Heine Lisa Wipperman returned 67,413 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Miromatrix Medical Inc. (0001527096) (Issuer)

      12/13/23 4:51:18 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maag Peter returned 58,368 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Miromatrix Medical Inc. (0001527096) (Issuer)

      12/13/23 4:50:50 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Craig Hallum initiated coverage on Miromatrix Medical with a new price target

      Craig Hallum initiated coverage of Miromatrix Medical with a rating of Buy and set a new price target of $22.00

      7/19/21 8:16:42 AM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MIRO
    Financials

    Live finance-specific insights

    See more
    • Miromatrix Reports Third Quarter 2023 Results

      EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

      11/14/23 4:05:00 PM ET
      $MIRO
      $UTHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

      EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update. "Miromatrix remains on pace to submit a response to the FDA's clinical hold letter relating to our miroliverELAPtm IND application in the second half of 2023," said Jeff Ross, Ph.D., Miromatrix CEO. "We continue to progress towards our goal of gaining authorization from the FDA to initiate a Phase 1 clinical trial to treat patients suffering from acute liver failure and

      8/14/23 4:01:00 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Miromatrix to Report Second Quarter 2023 Financial Results

      EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 866-652-5200 for domestic callers or 412-317-6060 for international callers. Please reference Conference ID: 10181369. To l

      7/25/23 4:01:00 PM ET
      $MIRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care